Your search history is turned on.
Date: March 28, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Saskatchewan
Microsoft Word - a53916708-release InterSystems et BioStrand, filiale dIPA, collaborent au lancement de lintgration innovante de la recherche vectorielle et de LENSai dans les applications de soins de sant pilotes par lIA VICTORIA, Colombie-Britannique--(BUSINESS WIRE)--March 28, 2024--IPA (IMMUNOPRECISE ANTIBODIES LTD) (la Socit ou IPA) (NASDAQ : ...
InterSystems and IPAs Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications InterSystems and IPAs Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications VICTORIA, British Columbia--(BUSINESS WIRE)...
Date: March 20, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Saskatchewan
Microsoft Word - a53912831-release IPA acquiert l'instrument Carterra LSA pour amliorer la dcouverte d'anticorps et renforcer ses dveloppements en matire d'IA Un dbit important de LSA pour faire progresser le dveloppement de mdicaments ax sur la diversit et les donnes d'IPA et pour enrichir LENSai. VICTORIA, Colombie-Britannique--(BUSINESS WIRE)--Mar...
IPA Acquires the Carterra LSA Instrument to Enhance Antibody Discovery and Bolster Its AI Developments IPA Acquires the Carterra LSA Instrument to Enhance Antibody Discovery and Bolster Its AI Developments Significant throughput of LSA to advance IPAs diversity- and data-driven drug development and to enrich LENSai. VICTORIA, British Columbia--(BUSI...
Date: March 14, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Saskatchewan
Microsoft Word - ImmunoPreciseAntibodies-031324FR IPA prsente ses rsultats financiers et les rcents points forts de son activit pour le troisime trimestre de lexercice 2024* IPA annonce un quatrime trimestre conscutif de hausse des revenus VICTORIA, Colombie-Britannique--(BUSINESS WIRE)--March 14, 2024--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (la socit ...
Microsoft Word - a53910222-release.htm IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024* IPA reports a fourth consecutive quarter of increased revenue. VICTORIA, British Columbia--(BUSINESS WIRE)--March 14, 2024--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the Company or IPA) (NASDAQ: IPA), an artificial intelligence-...
Microsoft Word - CFO Certification.docx 1 Form 52-109F2 Certification of Interim Filings Full Certificate I, Kristin Taylor, Chief Financial Officer, ImmunoPrecise Antibodies, Ltd., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of ImmunoPrecise Antibodies, Lt...
Microsoft Word - CEO Certification.docx 1 Form 52-109F2 Certification of Interim Filings Full Certificate I, Jennifer Bath, Chief Executive Officer, ImmunoPrecise Antibodies, Ltd., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of ImmunoPrecise Antibodies, Ltd. (t...
Microsoft Word - MD&A - Q3 January 31, 2024.docx IMMUNOPRECISE ANTIBODIES LTD. MANAGEMENT DISCUSSION AND ANALYSIS FOR THE THREE AND NINE MONTHS ENDED JANUARY 31, 2024 1 The following Managements Discussion and Analysis (MD&A) should be read in conjunction with the unaudited condensed interim consolidated financial statements of ImmunoPrecise Antibodies Lt...
Microsoft Word - Financial Statements Q3 January 31, 2024.docx IMMUNOPRECISE ANTIBODIES LTD. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS For the three and nine months ended January 31, 2024 and 2023 (Unaudited - Expressed in Canadian Dollars) IMMUNOPRECISE ANTIBODIES LTD. CONDENSED INTERIM CONSOLIDATED STAT...